Cyclo Therapeutics Stock Revenue
| CYTHW Stock | USD 0.14 0.04 22.22% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.1 M | 995.2 K |
Cyclo | Revenue |
Cyclo Therapeutics Company Revenue Analysis
Cyclo Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Cyclo Therapeutics Revenue | 1.08 M |
Most of Cyclo Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Cyclo
Projected quarterly revenue analysis of Cyclo Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Cyclo Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Cyclo Therapeutics' stock price.
Cyclo Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclo Therapeutics is extremely important. It helps to project a fair market value of Cyclo Stock properly, considering its historical fundamentals such as Revenue. Since Cyclo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclo Therapeutics' interrelated accounts and indicators.
| -0.14 | -0.26 | 0.74 | 0.68 | 0.73 | ||
| -0.14 | -0.1 | -0.35 | -0.38 | 0.07 | ||
| -0.26 | -0.1 | -0.25 | -0.31 | -0.77 | ||
| 0.74 | -0.35 | -0.25 | 0.4 | 0.51 | ||
| 0.68 | -0.38 | -0.31 | 0.4 | 0.62 | ||
| 0.73 | 0.07 | -0.77 | 0.51 | 0.62 |
Click cells to compare fundamentals
Cyclo Revenue Historical Pattern
Today, most investors in Cyclo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclo Therapeutics revenue as a starting point in their analysis.
Cyclo Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Cyclo Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Cyclo Therapeutics reported 1.08 M of revenue. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is notably lower than that of the firm.
Cyclo Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in revenue category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Number Of Shares Shorted | 100 | ||||
| Revenue | 1.08 M | ||||
| EBITDA | (20.03 M) | ||||
| Net Income | (20.06 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.03 M | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (16.19 M) | ||||
| Beta | -0.38 | ||||
| Market Capitalization | 62.76 M | ||||
| Total Asset | 13.25 M | ||||
| Retained Earnings | (83.86 M) | ||||
| Working Capital | 3.85 M | ||||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.